We studied 16 patients with stable COPD in a double blind, double dummy, placebo-controlled, within patient study to see if formoterol could be used as a rescue drug. We compared the of onset of bronchodilation obtained with formoterol 12 microg (metered dose corresponding to 9 microg delivered dose) and formoterol 24 microg (metered dose corresponding to 18 microg delivered dose), both delivered via Turbuhaler, with that of salbutamol 400 microg and salbutamol 800 microg delivered via pressurized metered-dose inhaler (pMDI). Patients inhaled single doses of placebo, formoterol and salbutamol on five separate days. FEV1 was measured in baseline condition and 3, 6, 9, 12, 15, 18, 21, 24, 30, 40, 50, and 60 min after inhalation of each treatm...
In the present study, we examined whether there is a difference in the onset of bronchodilatation be...
AbstractWorsening of underlying bronchospasm may be associated with acute exacerbations of chronic o...
AbstractThirty-six adult patients (16 women) with mild to moderate asthma with a mean baseline force...
AbstractFormoterol fumarate is a β2-agonist bronchodilator that combines a fast onset of action with...
Formoterol Turbuhaler has been suggested for as-needed use in asthmatic patients. We investigated wh...
Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, form...
The aim of the study was to investigate the time of onset and the duration of the bronchodilating ef...
AbstractThe aim of the study was to investigate the time of onset and the duration of the bronchodil...
The aim of this double-blind, double-dummy, cross-over, randomized, pilot study was to compare the a...
BACKGROUND: Bronchodilator therapy is central to the symptomatic management of chronic obstructi...
Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators....
Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuh...
The aim of this study was to investigate formoterol, an inhaled longacting b2-agonist, in patients w...
AbstractWe examined the influence of higher than conventional doses of oxitropium bromide on formote...
In the present study, we examined whether there is a difference in the onset of bronchodilatation be...
AbstractWorsening of underlying bronchospasm may be associated with acute exacerbations of chronic o...
AbstractThirty-six adult patients (16 women) with mild to moderate asthma with a mean baseline force...
AbstractFormoterol fumarate is a β2-agonist bronchodilator that combines a fast onset of action with...
Formoterol Turbuhaler has been suggested for as-needed use in asthmatic patients. We investigated wh...
Several clinical trials have shown that the inhaled beta2-agonists with long-acting properties, form...
The aim of the study was to investigate the time of onset and the duration of the bronchodilating ef...
AbstractThe aim of the study was to investigate the time of onset and the duration of the bronchodil...
The aim of this double-blind, double-dummy, cross-over, randomized, pilot study was to compare the a...
BACKGROUND: Bronchodilator therapy is central to the symptomatic management of chronic obstructi...
Background Most of the currently available inhaled beta-2 agonists are short acting bronchodilators....
Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuh...
The aim of this study was to investigate formoterol, an inhaled longacting b2-agonist, in patients w...
AbstractWe examined the influence of higher than conventional doses of oxitropium bromide on formote...
In the present study, we examined whether there is a difference in the onset of bronchodilatation be...
AbstractWorsening of underlying bronchospasm may be associated with acute exacerbations of chronic o...
AbstractThirty-six adult patients (16 women) with mild to moderate asthma with a mean baseline force...